08:38 AM EDT, 07/10/2024 (MT Newswires) -- Exscientia ( EXAI ) said Wednesday it has expanded its collaboration with Amazon (AMZN) Web Services to integrate artificial intelligence and machine learning services into its drug discovery platform.

The drug discovery company said its platform uses AWS technologies to integrate AI drug design and robotic lab automation, aiming to support the development of drug candidates at lower costs and faster pace, according to Exscientia ( EXAI ).

The collaboration includes the use of generative AI models and AWS's scalable cloud services to optimize the drug design, synthesis, and testing process, Exscientia ( EXAI ) added.

Shares of Exscientia ( EXAI ) were up 6.4% in recent Wednesday premarket activity.

Price: 6.19, Change: +0.37, Percent Change: +6.36